Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma

mAbs

Volumn 4, Issue 2, 2012, Pages 256-266

  Li, Su ^a   Zhang, Dongsheng ^a   Sun, Jian ^a   Li, Zhinming ^a   Deng, Liting ^a   Zou, Benyan ^a   Zhan, Jing ^a   Jiang, Wenqi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Anti CD22 monoclonal antibody; Pharmacokinetics; Tolerance

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR; CD22 ANTIGEN; CHIMERIC ANTIBODY; CREATININE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LAMIVUDINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SM03; UNCLASSIFIED DRUG; CANCER ANTIBODY; CD22 PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CHINESE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUID THERAPY; FOLLICULAR LYMPHOMA; GASTROINTESTINAL HEMORRHAGE; HEPATITIS B; HISTOLOGY; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE ERYTHEMA; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OCCULT BLOOD; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; SMALL LYMPHOCYTIC LYMPHOMA; T LYMPHOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VOMITING; ANIMAL; CHINA; CLINICAL TRIAL; IMMUNOLOGY; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MOUSE; PATHOLOGY;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MICE; MIDDLE AGED; SIALIC ACID BINDING IG-LIKE LECTIN 2;

EID: 84863251185     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.4.2.19136     Document Type: Article

References (36)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J Clin 2002; 52:23-47; PMID:11814064; http://dx.doi.org/10.3322/canjclin.52.1.23.
2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. Hematol J 2000; 1:53-66; PMID:11920170; http://dx.doi.org/10.1038/sj.thj.6200013.
3. Multani P, White CA, Grillo-López A, Grillo-Lopez A. Non-Hodgkin's lymphoma: review of conventional treatments. Curr Pharm Biotechnol 2001; 2:279-91; PMID:11762410; http://dx.doi.org/10.2174/1389201013378581.
4. Fisher RI. Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma. Semin Oncol 2000; 27:2-8; PMID:11225996.
5. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, et al. Comparison of a secondgeneration combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327:1342-9; PMID:1383819; http://dx.doi.org/10.1056/ NEJM199211053271903.
6. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33; PMID:9704735.
7. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-32; PMID:9731049.
8. Turner A. Antibodies. In: Roitt I, Brostoff J, Male D, Editors. Immunology. New York: Mosby 2001; 65-86.
9. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998; 16:3257-63; PMID:9779699.
10. Fayad L, Patel H, Verhoef G. Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase I study. Blood 2006; 108:2711.
11. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103:1807-14; PMID:14615373; http://dx.doi.org/10.1182/blood-2003-07- 2466.
12. Clark EA. CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J Immunol 1993; 150:4715-8; PMID:8496586.
13. Dörken B, Moldenhauer G, Pezzutto A, Schwartz R, Feller A, Kiesel S, et al. HD39 (B3), a B lineagerestricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 1986; 136:4470-9; PMID:3086431.
14. Cesano A, Gayko U, Brannan C. Differential expression of CD22 by indolent and aggressive NHLs: implications for targeted immunotherapy. Blood 2002; 100:350.
15. Otipoby KL, Andersson KB, Draves KE, Klaus SJ, Farr AG, Kerner JD, et al. CD22 regulates thymusin-dependent responses and the lifespan of B cells. Nature 1996; 384:634-7; PMID:8967951; http://dx.doi.org/10.1038/384634a0.
16. Sato S, Tuscano JM, Inaoki M, Tedder TF. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol 1998; 10:287-97; PMID:9695185; http://dx.doi.org/10.1006/smim.1998.0121.
17. Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non- Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004; 10:5327-34; PMID:15328168; http://dx.doi.org/10.1158/1078-0432.CCR-04-0294.
18. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003; 9:3982-90; PMID:14506197.
19. National Cancer Institute Common Toxicity Criteria. Version 3.0. http://home earthlink.net/~johnres/ncitox/ncitox.html.
20. Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40:3147-54; PMID:7427932.
21. Nadler LM, Stashenko P, Hardy R, Schlossman SF. A monoclonal antibody defining a lymphoma-associated antigen in man. J Immunol 1980; 125:570-7; PMID:6156208.
22. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004; 10:2868-78; PMID:15102696; http://dx.doi.org/10.1158/1078-0432.CCR-03-0493.
23. Hernandez-Ilizaliturri F, Gada P, Repasky EA. Enhancement in anti-tumor activity of rituximab when combined with epratuzumab or apolizumab (Hu1D10) in a B-cell lymphoma severe combined immunodeficiency (SCID) mouse model. Blood 2002; 100:158.
24. Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008; 113:2714-23; PMID:18853418; http://dx.doi.org/10.1002/cncr.23890.
25. Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, et al. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 2006; 107:2826-32; PMID:17099879; http://dx.doi.org/10.1002/cncr.22342.
26. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:3051-9; PMID:12837807; http://dx.doi.org/10.1200/JCO.2003.01.082.
27. Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, et al. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39:1469-77; PMID:21610128; http://dx.doi.org/10.1124/dmd.111.039453.
28. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti- CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135-43; PMID:10963642.
29. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63:803-43; PMID:12662126; http://dx.doi.org/10.2165/00003495-200363080-00005.
30. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22:1170-80; PMID:21115603; http://dx.doi.org/10.1093/annonc/mdq583.
31. Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, et al. Rituximab administration and reactivation of HBV. Hepatitis Res Treat 2010; 2010:182067; http://dx.doi.org/10.1155/2010/182067.
32. Hans PG. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharcokinetic Pharmacodyn 2009; 36:407-20; http://dx.doi.org/10.1007/s10928-009- 9129-5.
33. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45:792-801; PMID:15951469; http://dx.doi.org/10.1177/0091270005277075.
34. Nolting A, Fox FE, Kovar A. Clinical drug development of cetuximab, a monoclonal antibody. In: Meibohm B, Ed. Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. Wiley 2007; 353-70.
35. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies - mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007; 10:84-96; PMID:17265746.
36. Fracasso PM, Burris H, 3rd, Arquette MA, Govindan R, Gao F, Wright LP, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007; 13:986-93; PMID:17289894; http://dx.doi.org/10.1158/1078-0432.CCR-06-1542.